Technical Analysis for AQS - Aequus Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade F 0.145 -6.45% -0.010
AQS closed down 6.45 percent on Wednesday, September 18, 2019, on 84 percent of normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical AQS trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -6.45%
20 DMA Support Bullish -6.45%
Inside Day Range Contraction -6.45%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -6.45%
Crossed Above 20 DMA Bullish -6.45%
MACD Bullish Signal Line Cross Bullish -6.45%
Pocket Pivot Bullish Swing Setup -6.45%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -3.33%
Lower Bollinger Band Walk Weakness 7.41%

Older signals for AQS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Aequus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products. The Company operates through the segment of sales and marketing of pharmaceutical drugs developed by the Company or by its collaborative partners. Its products include tacrolimus immediate releaser, which is an immunosuppressive therapy used for the treatment and prevention of acute rejection following organ transplantation; Vistitan, which is a ophthalmology product; Topiramate extended-release (XR), which is a once-daily topiramate product designed for patient compliance, and Oxcarbazepine XR, which is a once-daily oxcarbazepine product. Its development-stage pipeline includes various products in neurology and psychiatry. Its lead development-stage product candidate is AQS-1301. In addition, the Company is developing a pipeline of other central nervous system product candidates. It has over two preclinical-stage programs and a clinical-stage program in development.
Chemistry Medicine Pharmaceutical Neurochemistry Anticonvulsants Transplantation
Is AQS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 0.245
52 Week Low 0.12
Average Volume 51,517
200-Day Moving Average 0.1736
50-Day Moving Average 0.161
20-Day Moving Average 0.1513
10-Day Moving Average 0.149
Average True Range 0.0135
ADX 14.19
+DI 28.277
-DI 18.9746
Chandelier Exit (Long, 3 ATRs ) 0.1395
Chandelier Exit (Short, 3 ATRs ) 0.1755
Upper Bollinger Band 0.1668
Lower Bollinger Band 0.1358
Percent B (%b) 0.3
BandWidth 20.489095
MACD Line -0.003
MACD Signal Line -0.0034
MACD Histogram 0.0004
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.168
Resistance 3 (R3) 0.168 0.162 0.164
Resistance 2 (R2) 0.162 0.156 0.161 0.162
Resistance 1 (R1) 0.153 0.152 0.150 0.153 0.161
Pivot Point 0.147 0.147 0.145 0.146 0.147
Support 1 (S1) 0.138 0.141 0.135 0.138 0.129
Support 2 (S2) 0.132 0.137 0.131 0.128
Support 3 (S3) 0.123 0.132 0.126
Support 4 (S4) 0.123